Open AccessCell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma
Author(s) -
Takashi Eguchi,
Kyuichi Kadota,
Jamie E. Chaft,
Brent Evans,
John Kidd,
Kay See Tan,
Joseph Dycoco,
Kathryn A. Kolquist,
Thaylon Davis,
Stephanie Hamilton,
Kraig M. Yager,
Joshua T. Jones,
William D. Travis,
David R. Jones,
Anne Renee Hartman,
Prasad S. Adusumilli
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.9129
Subject(s) - medicine , lung cancer , interquartile range , stage (stratigraphy) , oncology , adenocarcinoma , proportional hazards model , cancer , lung , gastroenterology , pathology , biology , paleontology
The goals of our study were (a) to validate a molecular expression signature (cell cycle progression [CCP] score and molecular prognostic score [mPS; combination of CCP and pathological stage {IA or IB}]) that identifies stage I lung adenocarcinoma (ADC) patients with a higher risk of cancer-specific death following curative-intent surgical resection, and (b) to determine whether mPS stratifies prognosis within stage I lung ADC histological subtypes.